Quintessence Biosciences

Quintessence Biosciences is a biopharmaceutical company focusing on the development of protein-based therapeutics as anti-cancer agents.

Quintessence Biosciences, Inc., a biopharmaceutical company, develops novel protein-based therapeutics as anti-cancer agents. The company’s products include Evade RNase QBI-139 that causes tumor growth inhibition in breast, colorectal, non-small cell lung, ovarian, pancreatic, and prostate cancers; targeted EVade ribonucleases, a tumor targeting therapy; and EVade ribonuclease zymogens that are inactive enzyme precursors that proteolytically cleave to manifest their catalytic activity. Its products are based on the Evade ribonuclease technology that allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases.